Northwest Biotherapeutics (NWBio) (OTCQB:NWBO), a US biotechnology company developing DCVax personalised immune therapies for solid tumour cancers, has announced that Dr. Marnix Bosch, the company's chief technical officer, made a scientific presentation entitled 'DCVax-L–Associated Survival Extension Assessed Through Propensity Score Matching Analyses' at the 2026 Annual Meeting of the British Neuro-Oncology Society (BNOS).

The presentation addressed the association between DCVax-L treatment and patient survival using propensity score matching methodologies (PSM). The slide deck is now available on the Northwest Biotherapeutics website at nwbio.com.

Northwest Biotherapeutics focuses on developing personalised immunotherapy products that are designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis. The company has a broad platform technology for DCVax dendritic cell-based vaccines. Its lead programme involves DCVax-L treatment for glioblastoma (GBM).